The World Health Organization (WHO) Collaborating Centre for Patient Safety and the WHO World Alliance for Patient Safety, housed in Oakbrook Terrace and Oak Brook, Ill, have invited health ministries, health care provider organizations, health care professionals, patient safety advocates, consumers, and other interested parties to comment on five proposed, potentially lifesaving Patient Safety Solutions selected as priorities by the Collaborating Centres international steering committee.
PVT GmbH, Germany, a developer of diagnostic laboratory systems, and BioReference Laboratories Inc, Elmwood Park, NJ, an independent regional clinical lab, plan to install PVT’s RSA Pro system at BioReferences facility.
Nanostart AG, Germany, a nanotechnology investment company, is taking an investment position in Curiox Biosystems, Singapore, with a 16.5% investment in the start-up.
Nanogen Inc, San Diego, a developer of advanced diagnostic products, reports that Robert Saltmarsh, vice president and CFO, will retire at the end of Feb 2008.
Ipsogen, New Haven Conn, has inked a pilot agreement with pharmaceutical provider AstraZeneca, Wilmington, Del, to evaluate molecular services and products in cancer research.
Ventana Medical Systems Inc, Tucson, Ariz, which specializes in tissue-based cancer diagnostics, has received notification from Roche, Switzerland, of its intention to seek the election of directors to the board of directors of Ventana at the company’s annual meeting of stockholders in June 2008.
Nanogen Inc, San Diego, a developer of advanced diagnostic products, has filed a preliminary proxy statement with the Securities and Exchange Commission for a special meeting of its stockholders.
Bio-Rad Laboratories Inc, Hercules, Calif, a multinational manufacturer and distributor of life science research and clinical diagnostic products, is offering a product application note detailing how its ProteoMiner protein enrichment kits concentrate and enrich low- and medium-abundance proteins for biomarker discovery.
BioServe, Beltsville, Md, has introduced ControlMatch, a new line of fully annotated control DNA and serum samples that help biomedical researchers validate new biomarkers and early stage clinical trial drug candidates.
Genzyme Genetics, Cambridge, Mass, a nationwide provider of genetic testing and counseling services for physicians and patients, plans to participate in a multi-center Cancer and Leukemia Group B study that will include 1,700 newly diagnosed patients with chronic lymphocytic leukemia.